ReviewCurrent gastroenterology reports2015
Ulcerative Colitis: Update on Medical Management.
Review in Current gastroenterology reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Interventions for the management of abdominal pain in ulcerative colitis.The Cochrane database of systematic reviews · 2021Pooled it
- Mesenchymal stem cells for the treatment of ulcerative colitis: a systematic review and meta-analysis of experimental and clinical studies.Stem cell research & therapy · 2019Pooled it
- Integrated Metabolomic and Transcriptomic Analyses Reveal Alterations in the Serotonergic Synapse Pathway and a Robust Diagnostic Model in Ulcerative Colitis.Metabolites · 2026Article
- Oral Nano-Delivery of Crotoxin Modulates Experimental Ulcerative Colitis in a Mouse Model of Maximum Acute Inflammatory Response.International journal of molecular sciences · 2025Article
- Expression of MAF bZIP transcription factor B protects against ulcerative colitis through the inhibition of the NF-κB pathway.Immunity, inflammation and disease · 2024Article
- Article
- Strategies to improve the effect of mesenchymal stem cell therapy on inflammatory bowel disease.World journal of stem cells · 2022Review
- Anti-inflammatory effects of anemonin on acute ulcerative colitis via targeted regulation of protein kinase C-θ.Chinese medicine · 2022Article
- Cherry Polyphenol Extract Ameliorated Dextran Sodium Sulfate-Induced Ulcerative Colitis in Mice by Suppressing Wnt/β-Catenin Signaling Pathway.Foods (Basel, Switzerland) · 2021Article
- Determining Response to Treatment for Drug-Induced Bronchocentric Granulomatosis by the Forced Oscillation Technique.Medicina (Kaunas, Lithuania) · 2021Article
- Preclinical Pharmacokinetics and Acute Toxicity in Rats of 5-{[(2E)-3-Bromo-3-carboxyprop-2-enoyl]amino}-2-hydroxybenzoic Acid: A Novel 5-Aminosalicylic Acid Derivative with Potent Anti-Inflammatory Activity.Molecules (Basel, Switzerland) · 2021Article
- Combination of Enteral Nutrition and Probiotics Promote Recovery Following Ileal Pouch-Anal Anastomosis in Rats.Inflammation · 2021Article
- Protective Effect of Methane-Rich Saline on Acetic Acid-Induced Ulcerative Colitis via Blocking the TLR4/NF-Oxidative medicine and cellular longevity · 2019Article
- Andrographolide presents therapeutic effect on ulcerative colitis through the inhibition of IL-23/IL-17 axis.American journal of translational research · 2018Article
- Economic Evaluations of Treatments for Inflammatory Bowel Diseases: A Literature Review.Canadian journal of gastroenterology & hepatology · 2018Review
- Social considerations of inflammatory bowel disease in Southern Israel.BMJ case reports · 2017Article
- Berberine alleviates dextran sodium sulfate-induced colitis by improving intestinal barrier function and reducing inflammation and oxidative stress.Experimental and therapeutic medicine · 2017Article
- Article
- EGCG Maintains Th1/Th2 Balance and Mitigates Ulcerative Colitis Induced by Dextran Sulfate Sodium through TLR4/MyD88/NF-Canadian journal of gastroenterology & hepatology · 2017Article
- The Cost-Effectiveness of Vedolizumab for Inflammatory Bowel Disease: A Review of the Current Literature.Gastroenterology & hepatology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis (UC) is a chronic inflammatory bowel disease whose pathogenesis is multifactorial and includes influences from genes, the environment, and the gut microbiome. Recent advances in diagnosis and treatment have led to significant improvement in managing the disease. Disease monitoring with the use of therapeutic drug monitoring, stool markers, and assessment of mucosal healing have garnered much attention. The recent approval of vedolizumab for treatment of moderate to severe UC has been a welcome addition. Newer biologics, including those targeting the Janus tyrosine kinase (JAK) pathway, are on the horizon to add to the current armamentarium of anti-TNF alpha and anti-integrin therapies. The recent publication of the SCENIC consensus statement on surveillance and management of dysplasia in UC patients supports the use of chromoendoscopy over random biopsies in detecting dysplasia. This review highlights these recent advances along with others that have been made with ulcerative colitis.
Indexed as
Identifiers
26386686What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.